Repligen Corp

Repligen's jaw-dropping P/E of 135.2 reveals a market pricing in substantial future growth, yet the stock sits 9.76% short and trades below its 52-week high—suggesting skepticism beneath the premium valuation. With an RSI of 45.1, there's neither overbought nor oversold conditions, indicating neutral momentum despite the lofty multiple. For a biological products company, this valuation gap between price and earnings expectations creates tension: either the market has priced in aggressive expansion that may disappoint, or shorts are betting on a stumble that doesn't materialize. The fundamental disconnect warrants scrutiny before committing capital.